AGENCY FOR HEALTHCARE RESEARCH AND QUALITY
On Nov. 30, 2023, AHRQ hosted a webinar on pain management focused on findings from three recently published evidence reports conducted by the AHRQ EPC Program: (1) Nonopioid Pharmacologic Treatments for Chronic Pain, (2) Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain, and (3) Acute Treatments of Episodic Migraine. The authors of the reports, Roger Chou, M.D., FACP, M. Hassan Murad, M.D. and Zhen Wang, Ph.D., shared the main findings from the reports. After initial reactions from stakeholders who weighed in on evidence gaps and implications for the field, Lucy Savitz, Ph.D., M.B.A., AcademyHealth Board Chair, moderated a discussion with the broader audience.
CENTERS FOR DISEASE CONTROL AND PREVENTION
CENTERS FOR MEDICARE & MEDICAID SERVICES
The IBH Model builds upon earlier Innovation Center efforts to include community-based behavioral health practices, including both mental health providers and substance use disorder providers, in value-based care. The IBH Model is based on the lessons learned from previous Innovation Center models, such as the Maternal Opioid Misuse Model, Integrated Care for Kids Model, and the Value in Opioid Use Disorder Treatment Demonstration.
The model will launch in Fall 2024 and is anticipated to operate for eight years in up to eight states. CMS will release a Notice of Funding Opportunity for the model in Spring 2024.
Please visit the IBH Model webpage for more information.
For Frequently Asked Questions about the Innovation in Behavioral Health Model, click here
For a fact sheet on the model, click here
View a fact sheet of the accomplishments to date on the HHS Roadmap for Behavioral Health Integration.
FOOD AND DRUG ADMINISTRATION
This MOU establishes the terms for collaboration between FDA and HCV-TARGET to promote shared interests, which can be pursued through a variety of programs including collaborative
research.
FDA and GUMC share interests In promoting scientific progress through the exchange of scientific capital in the diverse disciplines that directly and Indirectly affect human and animal health and medicine.
To facilitate existing and new mutually agreed upon programs and activities and establish the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
he collaborative framework this MOU provides will facilitate existing and new mutually agreed upon programs and activities and establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
This MOU and the collaborative framework it provides will facilitate existing and new mutually agreed upon programs and activities, consortia and consensus development between the parties and establishes the terms for collaboration to promote shared interests.
This MOU establishes terms for collaboration to promote shared interests, which may be pursued through a variety of programs including collaborative education and research.
This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
This MOU establishes the terms for collaboration to promote FDA and University of Pittsburgh’s shared interests, which can be pursued through a variety of programs.
This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
Promote shared interests in various science-based academic initiatives, fellowships, internships, sabbaticals, research and scientific education.
HEALTH & HUMAN SERVICES
The Office for Human Research Protections (OHRP) has responsibility for oversight for the compliance of federal regulations for the protection of human research subjects as defined under 45 CFR Part 46, also known as the Common Rule. In carrying out this responsibility, OHRP reviews allegations of noncompliance involving human subject research projects that are either:
Directly supported by the U.S. Department of Health and Human Services (HHS), or
Being conducted at an institution that has an agreement in place under its Assurance of Compliance to provide OHRP jurisdiction over all research, regardless of source of support. (This is a voluntary amendment to the Federal Wide Assurance Agreement (FWA) and is not required by institutions.)
NATIONAL INSTITUTES OF HEALTH
NIH Director, Dr. Monica Bertagnolli announced today that the agency is accepting the Advisory Committee to the NIH Director (ACD) recommendations to catalyze the development and use of novel alternative methods. Through its Novel Alternative Methods (NAMs) Working Group, the ACD consulted with experts in the field and reviewed input from the community to deliver a final report in December 2023. The full report, including the recommendations can be viewed here.
Leveraging these recommendations and building upon existing NIH efforts, the NIH Common Fund has proposed a research program called Complement Animal Research in Experimentation (Complement-ARIE) that aims to accelerate the development of NAM technologies and build a suite of tools that could complement, or in some cases, replace traditional models for researchers to study human biology and disease. This program received concept clearance from the NIH Council of Councils at its January 25, 2024, meeting. More information can be found on the Complement-ARIE website.
Pain Consortium Grants and Announcement
Program on Public, Private-Partnership